Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15142883rdf:typepubmed:Citationlld:pubmed
pubmed-article:15142883lifeskim:mentionsumls-concept:C0023449lld:lifeskim
pubmed-article:15142883lifeskim:mentionsumls-concept:C0037083lld:lifeskim
pubmed-article:15142883lifeskim:mentionsumls-concept:C0079904lld:lifeskim
pubmed-article:15142883lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:15142883lifeskim:mentionsumls-concept:C0034538lld:lifeskim
pubmed-article:15142883lifeskim:mentionsumls-concept:C0205217lld:lifeskim
pubmed-article:15142883lifeskim:mentionsumls-concept:C1710082lld:lifeskim
pubmed-article:15142883lifeskim:mentionsumls-concept:C1704259lld:lifeskim
pubmed-article:15142883lifeskim:mentionsumls-concept:C0683598lld:lifeskim
pubmed-article:15142883lifeskim:mentionsumls-concept:C1521725lld:lifeskim
pubmed-article:15142883lifeskim:mentionsumls-concept:C1705987lld:lifeskim
pubmed-article:15142883lifeskim:mentionsumls-concept:C1314939lld:lifeskim
pubmed-article:15142883lifeskim:mentionsumls-concept:C1516044lld:lifeskim
pubmed-article:15142883lifeskim:mentionsumls-concept:C0332183lld:lifeskim
pubmed-article:15142883pubmed:issue5lld:pubmed
pubmed-article:15142883pubmed:dateCreated2004-8-19lld:pubmed
pubmed-article:15142883pubmed:abstractTextTo investigate possible causes of the variable response to treatment in pediatric B-precursor acute lymphoblastic leukemia (ALL) and to establish potential novel therapeutic targets, we used ionizing radiation (IR) exposure as a model of DNA damage formation to identify tumors with resistance to p53-dependent apoptosis. Twenty-one of 40 ALL tumors responded normally to IR, exhibiting accumulation of p53 and p21 proteins and cleavage of caspases 3, 7, and 9 and of PARP1. Nineteen tumors exhibited apoptotic resistance and lacked PARP1 and caspase cleavage; although 15 of these tumors had normal accumulation of p53 and p21 proteins, examples exhibited abnormal expression of TRAF5, TRAF6, and cIAP1 after IR, suggesting increased NF-kappaB prosurvival signaling as the mechanism of apoptotic resistance. The presence of a hyperactive PARP1 mutation in one tumor was consistent with such increased NF-kappaB activity. PARP1 inhibition restored p53-dependent apoptosis after IR in these leukemias by reducing NF-kappaB DNA binding and transcriptional activity. In the remaining 4 ALL tumors, apoptotic resistance was associated with a TP53 mutation or with defective activation of p53. We conclude that increased NF-kappaB prosurvival signaling is a frequent mechanism by which B-precursor ALL tumors develop apoptotic resistance to IR and that PARP1 inhibition may improve the DNA damage response of these leukemias.lld:pubmed
pubmed-article:15142883pubmed:languageenglld:pubmed
pubmed-article:15142883pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15142883pubmed:citationSubsetAIMlld:pubmed
pubmed-article:15142883pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15142883pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15142883pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15142883pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15142883pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15142883pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15142883pubmed:statusMEDLINElld:pubmed
pubmed-article:15142883pubmed:monthSeplld:pubmed
pubmed-article:15142883pubmed:issn0006-4971lld:pubmed
pubmed-article:15142883pubmed:authorpubmed-author:YeoG NGNlld:pubmed
pubmed-article:15142883pubmed:authorpubmed-author:StankovicTatj...lld:pubmed
pubmed-article:15142883pubmed:authorpubmed-author:MossPaul A...lld:pubmed
pubmed-article:15142883pubmed:authorpubmed-author:WeiWenbinWlld:pubmed
pubmed-article:15142883pubmed:authorpubmed-author:GriffithsMike...lld:pubmed
pubmed-article:15142883pubmed:authorpubmed-author:TaylorA...lld:pubmed
pubmed-article:15142883pubmed:authorpubmed-author:DarbyshirePhi...lld:pubmed
pubmed-article:15142883pubmed:authorpubmed-author:AustenBelinda...lld:pubmed
pubmed-article:15142883pubmed:authorpubmed-author:WestonVictori...lld:pubmed
pubmed-article:15142883pubmed:authorpubmed-author:MarstonEliotElld:pubmed
pubmed-article:15142883pubmed:authorpubmed-author:LawsonSarahSlld:pubmed
pubmed-article:15142883pubmed:authorpubmed-author:HillFrankFlld:pubmed
pubmed-article:15142883pubmed:authorpubmed-author:MannJill RJRlld:pubmed
pubmed-article:15142883pubmed:issnTypePrintlld:pubmed
pubmed-article:15142883pubmed:day1lld:pubmed
pubmed-article:15142883pubmed:volume104lld:pubmed
pubmed-article:15142883pubmed:ownerNLMlld:pubmed
pubmed-article:15142883pubmed:authorsCompleteYlld:pubmed
pubmed-article:15142883pubmed:pagination1465-73lld:pubmed
pubmed-article:15142883pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:meshHeadingpubmed-meshheading:15142883...lld:pubmed
pubmed-article:15142883pubmed:year2004lld:pubmed
pubmed-article:15142883pubmed:articleTitleApoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-kappaB survival pathway signaling.lld:pubmed
pubmed-article:15142883pubmed:affiliationCancer Research UK Institute for Cancer Studies, Birmingham University, Edgbaston, Birmingham, B15 2TT, United Kingdom. victoriaw@cancer.bham.ac.uklld:pubmed
pubmed-article:15142883pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15142883pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15142883lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15142883lld:pubmed